Cargando…

Get Off on the Right Foot: How to Plan an Efficient Leukocytapheresis to Collect T Cells for CAR T-Cell Manufacturing

BACKGROUND: The major drug regulatory agencies have approved chimeric antigen receptor (CAR) T cells for the treatment of some B-cell lymphoproliferative diseases. Their use is expanding, and new indications will be approved. Efficient mononuclear cell collection by apheresis providing enough T cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piñeyroa, Juan A., Cid, Joan, Lozano, Miquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098271/ https://www.ncbi.nlm.nih.gov/pubmed/37066050 http://dx.doi.org/10.1159/000528331

Ejemplares similares

Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry
por: Fernandez-Sojo, Jesus, et al.
Publicado: (2022)

Leukocytapheresis in Chronic Myeloid Leukemia With Leukostasis
por: Raghuwanshi, Babita, et al.
Publicado: (2020)

Leukocytapheresis in patients with inflammatory bowel diseases
por: Woźniak, Małgorzata, et al.
Publicado: (2021)

LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS
por: Krznarić, Željko, et al.
Publicado: (2019)

Peripheral Leukocytapheresis Attenuates Acute Lung Injury Induced by Lipopolysaccharide In Vivo
por: He, Zhi-Gao, et al.
Publicado: (2012)

Adsorptive Leukocytapheresis in Inflammatory Bowel Diseases: Our Preliminary Results are Encouraging
por: Törüner, Murat, et al.
Publicado: (2013)

Right on target: CNGS gets off to an excellent start
Publicado: (2006)

Right on target: CNGS gets off to an excellent start
por: Elsener, K, et al.
Publicado: (2006)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

Leukocytapheresis Therapy Improved Cholestasis in a Patient Suffering from Primary Sclerosing Cholangitis with Ulcerative Colitis
por: Itou, Minoru, et al.
Publicado: (2009)

Getting the right cells
por: Cakir, Bilal, et al.
Publicado: (2022)

Starting off on the right foot: strong right-footers respond faster with the right foot to positive words and with the left foot to negative words
por: de la Vega, Irmgard, et al.
Publicado: (2015)

Impact of Manufacturing Procedures on CAR T Cell Functionality
por: Watanabe, Norihiro, et al.
Publicado: (2022)

T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
por: Battram, Anthony M., et al.
Publicado: (2022)

Write your business plan: get your plan in place and your business off the ground
por: Primento Digital
Publicado: (2016)

Rapid manufacturing of non-activated potent CAR T cells
por: Ghassemi, Saba, et al.
Publicado: (2022)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis
por: Kobayashi, Taku, et al.
Publicado: (2017)

Ten things to get right for marine conservation planning in the Coral Triangle
por: Weeks, Rebecca, et al.
Publicado: (2015)

Clinical manufacturing of CAR T cells: foundation of a promising therapy
por: Wang, Xiuyan, et al.
Publicado: (2016)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Steering CAR T cell epigenetic programs by tweaking manufacturing protocol
por: Dukes, Meghan W., et al.
Publicado: (2023)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Caplacizumab as frontline therapy in addition to standard treatment in iTTP
por: Cid, Joan, et al.
Publicado: (2022)

Get the right access rights!
por: Rosaria Marraffino
Publicado: (2015)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

Sustained effect of leukocytapheresis/granulocytapheresis versus anti-human TNF-α monoclonal antibody on ulcerative colitis: A 2-year retrospective study
por: Sakai, Masahiro, et al.
Publicado: (2023)

Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
por: Tyagarajan, Seshu, et al.
Publicado: (2019)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
por: Agarwalla, Pritha, et al.
Publicado: (2022)

Commentary: Getting off the DESK!
por: Chaturvedi, Isha, et al.
Publicado: (2022)

COVID-19 ARDS: getting ventilation right
por: Pérez-Fernández, Xosé L, et al.
Publicado: (2022)

PB2185: MINIMAL RESIDUAL DISEASE AND THE NUMBER OF CD34+ CELLS CIRCULATING IN THE PERIPHERAL BLOOD OF MULTIPLE MYELOMA PATIENTS ON THE DAY OF THE FIRST SESSION OF LEUKOCYTAPHERESIS DURING AUTOGRAFT HARVESTING
por: Kostroma, I., et al.
Publicado: (2022)

Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells
por: Sayadmanesh, Ali, et al.
Publicado: (2023)

Babies get it right
por: Hadley, Hillary, et al.
Publicado: (2015)

The countries getting it right
por: Hamzelou, Jessica
Publicado: (2020)

Getting the metabolites right
por: Korte, Arthur
Publicado: (2021)

Getting Road Expansion on the Right Track: A Framework for Smart Infrastructure Planning in the Mekong
por: Balmford, Andrew, et al.
Publicado: (2016)

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
por: Balke-Want, Hyatt, et al.
Publicado: (2023)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ujot28vc119jnv8uugv03f16qc